検索画面
細胞材料開発室サイト

戻る 戻る
RCB4455 : PC-9  update : 2018/08/02
細胞特性(Comment:英)Human cell line derived from lung adenocarcinoma cells. Differentiated type. Previous name:PC-14(RCB0446)
細胞特性(日)ヒト肺腺癌(分化型)由来細胞株。旧提供:RCB0446 PC-14
細胞特性(寄託者記述:英)
細胞特性(寄託者記述:日)
使用条件(英)Basically, there is no restriction regarding academic use.
使用条件(日)学術研究における利用につきましては原則として使用制限はありません。
備考(英)
備考(日)
提供申込書類 依頼書C-0001.pdf   同意書(非営利)C-0003.pdf   同意書(営利)C-0003p.pdf  
提供同意書は、使用機関及び使用内容に応じて二種類あります。該当する提供同意書をご使用ください(詳細)。特許等の取得及び商業利用等は別途ご相談(cellbank.brc@riken.jp)を承ります。
提供手数料 手数料とお支払いについてはこちらをご覧ください。
細胞基本情報 樹立者 Tsuji, K. & Hayata, Y.
寄託日 1989
別名 RCB0446 PC-14
動物種 human < Mammals
属名 Homo
種名 sapiens
人種 Japanese
採取組織 lung
細胞分類 cancer
細胞寿命 infinite
細胞形態 other
細胞培養・検査情報
寄託時情報
ロット情報
培地・試薬情報 培地・試薬一覧はこちらをご覧ください。
培養形態 Adherent cells
培地 RPMI1640 + 10% FBS
抗生物質 Free
継代方法 pipetting or 0.25% trypsin
継代密度 1 : 8 split
継代・培地交換頻度 Subculture : 1-2 times/week, Medium Renewal : 2 times/week
培養最適温度 37 ℃
二酸化炭素濃度 5 %
凍結培地 Medium + 10% DMSO
凍結方法 Slow freezing
マイコプラズマ (-)
個体識別検査 OK
アイソザイム検査 LD, NP
画像情報
寄託時情報
ロット情報
文献情報 Reference(英) 0件
Reference(日) 0件
利用者成果(英) 33件
利用者成果(日) 0件

トップへページトップへ
Reference(英)

トップへページトップへ
Reference(日)

トップへページトップへ
利用者成果(英)
7069  Kataoka K, Shiraishi Y, Takeda Y, Sakata S, Matsumoto M, Nagano S, Maeda T, Nagata Y, Kitanaka A, Mizuno S, Tanaka H, Chiba K, Ito S, Watatani Y, Kakiuchi N, Suzuki H, Yoshizato T, Yoshida K, Sanada M, Itonaga H, Imaizumi Y, Totoki Y, Munakata W, Nakamura H, Hama N, Shide K, Kubuki Y, Hidaka T, Kameda T, Masuda K, Minato N, Kashiwase K, Izutsu K, Takaori-Kondo A, Miyazaki Y, Takahashi S, Shibata T, Kawamoto H, Akatsuka Y, Shimoda K, Takeuchi K, Seya T, Miyano S, Ogawa S.  Aberrant PD-L1 expression through 3'-UTR disruption in multiple cancers.  Nature  2016  534:402-6  PubMed ID: 27281199
7103  Greig MJ, Niessen S, Weinrich SL, Feng JL, Shi M, Johnson TO.  Effects of Activating Mutations on EGFR Cellular Protein Turnover and Amino Acid Recycling Determined Using SILAC Mass Spectrometry.  Int J Cell Biol  2015  2015:798936  PubMed ID: 26689952
7346  Yen HY, Liu YC, Chen NY, Tsai CF, Wang YT, Chen YJ, Hsu TL, Yang PC, Wong CH.  Effect of sialylation on EGFR phosphorylation and resistance to tyrosine kinase inhibition.  Proc. Natl. Acad. Sci. U.S.A.  2015  112:6955-60  PubMed ID: 25971727
7402  Sugita S, Ito K, Yamashiro Y, Moriya S, Che XF, Yokoyama T, Hiramoto M, Miyazawa K.  EGFR-independent autophagy induction with gefitinib and enhancement of its cytotoxic effect by targeting autophagy with clarithromycin in non-small cell lung cancer cells.  Biochem. Biophys. Res. Commun.  2015  461:28-34  PubMed ID: 25858318
7498  Sakamoto T, Kodani M, Takata M, Chikumi H, Nakamoto M, Nishii-Ito S, Ueda Y, Izumi H, Makino H, Touge H, Takeda K, Yamasaki A, Yanai M, Tanaka N, Igishi T, Shimizu E.  A novel point-of-care system for high-speed real-time polymerase chain reaction testing for epidermal growth factor receptor mutations in bronchial lavage fluids after transbronchial biopsy in patients with non-small cell lung cancer.  Int. J. Oncol.  2015  46:1473-80  PubMed ID: 25651992
7523  Elza C. de Bruin, Ming Jiang, Michael Howell, Julian Downward  Genome-Wide siRNA Screen for Anti-Cancer Drug Resistance in Adherent Cell Lines.  Bio-protocol  2015  5:e1474 
9511  Yamaguchi T, Lu C, Ida L, Yanagisawa K, Usukura J, Cheng J, Hotta N, Shimada Y, Isomura H, Suzuki M, Fujimoto T, Takahashi T.  ROR1 sustains caveolae and survival signalling as a scaffold of cavin-1 and caveolin-1.  Nat Commun  2016  7:10060  PubMed ID: 26725982
9598  Kurimoto R, Iwasawa S, Ebata T, Ishiwata T, Sekine I, Tada Y, Tatsumi K, Koide S, Iwama A, Takiguchi Y.  Drug resistance originating from a TGF-β/FGF-2-driven epithelial-to-mesenchymal transition and its reversion in human lung adenocarcinoma cell lines harboring an EGFR mutation.  Int. J. Oncol.  2016  48:1825-36  PubMed ID: 26984042
9884  Watarai H, Okada M, Kuramoto K, Takeda H, Sakaki H, Suzuki S, Seino S, Oizumi H, Sadahiro M, Kitanaka C.  Impact of H3K27 Demethylase Inhibitor GSKJ4 on NSCLC Cells Alone and in Combination with Metformin.  Anticancer Res.  2016  36:6083-6092  PubMed ID: 27793936
10010  Koh V, Kwan HY, Tan WL, Mah TL, Yong WP.  Knockdown of POLA2 increases gemcitabine resistance in lung cancer cells.  BMC Genomics  2016  17:1029  PubMed ID: 28155658
10132  Liu Z, Yanagisawa K, Griesing S, Iwai M, Kano K, Hotta N, Kajino T, Suzuki M, Takahashi T.  TTF-1/NKX2-1 binds to DDB1 and confers replication stress resistance to lung adenocarcinomas.  Oncogene  2017  36:3740-3748  PubMed ID: 28192407
10280  Seike M, Kim CH, Zou F, Noro R, Chiba M, Ishikawa A, Κunugi S, Kubota K, Gemma A.  AXL and GAS6 co-expression in lung adenocarcinoma as a prognostic classifier.  Oncol. Rep.  2017  37:3261-3269  PubMed ID: 28440492
10317  Kurimoto R, Ebata T, Iwasawa S, Ishiwata T, Tada Y, Tatsumi K, Takiguchi Y.  Pirfenidone may revert the epithelial-to-mesenchymal transition in human lung adenocarcinoma.  Oncol Lett  2017  14:944-950  PubMed ID: 28693256
10530  Niessen S, Dix MM, Barbas S, Potter ZE, Lu S, Brodsky O, Planken S, Behenna D, Almaden C, Gajiwala KS, Ryan K, Ferre R, Lazear MR, Hayward MM, Kath JC, Cravatt BF.  Proteome-wide Map of Targets of T790M-EGFR-Directed Covalent Inhibitors.  Cell Chem Biol  2017  24:1388-1400.e7  PubMed ID: 28965727
10633  Asaka S, Yoshizawa A, Nakata R, Negishi T, Yamamoto H, Shiina T, Shigeto S, Matsuda K, Kobayashi Y, Honda T.  Utility of bronchial lavage fluids for epithelial growth factor receptor mutation assay in lung cancer patients: Comparison between cell pellets, cell blocks and matching tissue specimens.  Oncol Lett  2018  15:1469-1474  PubMed ID: 29399190
10679  Yoneda K, Chikaishi Y, Kuwata T, Ohnaga T, Tanaka F.  Capture of mesothelioma cells with 'universal' CTC-chip.  Oncol Lett  2018  15:2635-2640  PubMed ID: 29434985
10706  Bao H, Bai T, Takata K, Yokobori T, Ohnaga T, Hisada T, Maeno T, Bao P, Yoshida T, Kumakura Y, Honjo H, Sakai M, Sohda M, Fukuchi M, Altan B, Handa T, Ide M, Miyazaki T, Ogata K, Oyama T, Shimizu K, Mogi A, Asao T, Shirabe K, Kuwano H, Kaira K.  High expression of carcinoembryonic antigen and telomerase reverse transcriptase in circulating tumor cells is associated with poor clinical response to the immune checkpoint inhibitor nivolumab.  Oncol Lett  2018  15:3061-3067  PubMed ID: 29435038
10721  Sato H, Sakaguchi M, Yamamoto H, Tomida S, Aoe K, Shien K, Yoshioka T, Namba K, Torigoe H, Soh J, Tsukuda K, Tao H, Okabe K, Miyoshi S, Pass HI, Toyooka S.  Therapeutic potential of targeting S100A11 in malignant pleural mesothelioma.  Oncogenesis  2018  7:11  PubMed ID: 29362358
10768  Kashima Y, Suzuki A, Liu Y, Hosokawa M, Matsunaga H, Shirai M, Arikawa K, Sugano S, Kohno T, Takeyama H, Tsuchihara K, Suzuki Y.  Combinatory use of distinct single-cell RNA-seq analytical platforms reveals the heterogeneous transcriptome response.  Sci Rep  2018  8:3482  PubMed ID: 29472726
10784  Senju H, Kumagai A, Nakamura Y, Yamaguchi H, Nakatomi K, Fukami S, Shiraishi K, Harada Y, Nakamura M, Okamura H, Tanaka Y, Mukae H.  Effect of IL-18 on the Expansion and Phenotype of Human Natural Killer Cells: Application to Cancer Immunotherapy.  Int. J. Biol. Sci.  2018  14:331-340  PubMed ID: 29559850
10785  Torigoe H, Yamamoto H, Sakaguchi M, Youyi C, Namba K, Sato H, Shien K, Soh J, Suzawa K, Tomida S, Tsukuda K, Miyoshi S, Toyooka S.  Tumor-suppressive effect of LRIG1, a negative regulator of ErbB, in non-small cell lung cancer harboring mutant EGFR.  Carcinogenesis  2018  39:719-727  PubMed ID: 29546323
11038  Saito R, Miki Y, Ishida N, Inoue C, Kobayashi M, Hata S, Yamada-Okabe H, Okada Y, Sasano H.  The Significance of MMP-1 in EGFR-TKI-Resistant Lung Adenocarcinoma: Potential for Therapeutic Targeting  Int J Mol Sci  2018  19. pii: E609  PubMed ID: 29463039
11201  Cao S, Wang Z, Gao X, He W, Cai Y, Chen H, Xu R.  FOXC1 induces cancer stem cell-like properties through upregulation of beta-catenin in NSCLC.  J. Exp. Clin. Cancer Res.  2018    PubMed ID: 30189871
11307  Minagawa A, Yoshikawa T, Yasukawa M, Hotta A, Kunitomo M, Iriguchi S, Takiguchi M, Kassai Y, Imai E, Yasui Y, Kawai Y, Zhang R, Uemura Y, Miyoshi H, Nakanishi M, Watanabe A, Hayashi A, Kawana K, Fujii T, Nakatsura T, Kaneko S.  Enhancing T Cell Receptor Stability in Rejuvenated iPSC-Derived T Cells Improves Their Use in Cancer Immunotherapy.  Cell Stem Cell  2018    PubMed ID: 30449714
11336  Kosibaty Z, Murata Y, Minami Y, Dai T, Kano J, Matsuoka R, Nakano N, Noguchi M.  Cytoplasmic expression of epithelial cell transforming sequence 2 in lung adenocarcinoma and its implications for malignant progression.  Lab. Invest.  2019    PubMed ID: 30542068
11372  Sun Y, Bandi M, Lofton T, Smith M, Bristow CA, Carugo A, Rogers N, Leonard P, Chang Q, Mullinax R, Han J, Shi X, Seth S, Meyers BA, Miller M, Miao L, Ma X, Feng N, Giuliani V, Geck Do M, Czako B, Palmer WS, Mseeh F, Asara JM, Jiang Y, Morlacchi P, Zhao S, Peoples M, Tieu TN, Warmoes MO, Lorenzi PL, Muller FL, DePinho RA, Draetta GF, Toniatti C, Jones P, Heffernan TP, Marszalek JR.  Functional Genomics Reveals Synthetic Lethality between Phosphogluconate Dehydrogenase and Oxidative Phosphorylation.  Cell Rep  2019    PubMed ID: 30625329
11384  Taniguchi H, Yamada T, Wang R, Tanimura K, Adachi Y, Nishiyama A, Tanimoto A, Takeuchi S, Araujo LH, Boroni M, Yoshimura A, Shiotsu S, Matsumoto I, Watanabe S, Kikuchi T, Miura S, Tanaka H, Kitazaki T, Yamaguchi H, Mukae H, Uchino J, Uehara H, Takayama K, Yano S.  AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells.  Nat Commun  2019    PubMed ID: 30651547
11421  Masuda T, Nakashima T, Namba M, Yamaguchi K, Sakamoto S, Horimasu Y, Miyamoto S, Iwamoto H, Fujitaka K, Miyata Y, Hamada H, Okada M, Hattori N.  Inhibition of PAI-1 limits chemotherapy resistance in lung cancer through suppressing myofibroblast characteristics of cancer-associated fibroblasts.  J. Cell. Mol. Med.  2019    PubMed ID: 30734495
11453  Kobayashi M, Saito R, Miki Y, Nanamiya R, Inoue C, Abe J, Sato I, Okada Y, Sasano H.  The correlation of p22phox and chemosensitivity in EGFR-TKI resistant lung adenocarcinoma.  Oncotarget  2019    PubMed ID: 30800222
11461  Imabayashi T, Uchino J, Osoreda H, Tanimura K, Chihara Y, Tamiya N, Kaneko Y, Yamada T, Takayama K.  Nicotine Induces Resistance to Erlotinib Therapy in Non-Small-Cell Lung Cancer Cells Treated with Serum from Human Patients.  Cancers (Basel)  2019    PubMed ID: 30818860
4141  Suzuki S, Okada M, Takeda H, Kuramoto K, Sanomachi T, Togashi K, Seino S, Yamamoto M, Yoshioka T, Kitanaka C.  Involvement of GLUT1-mediated glucose transport and metabolism in gefitinib resistance of non-small-cell lung cancer cells.  Oncotarget  2018    PubMed ID: 30220973
4320  Takeuchi M, Doi T, Obayashi K, Hirai A, Yoneda K, Tanaka F, Iwai Y.  Soluble PD-L1 with PD-1-binding capacity exists in the plasma of patients with non-small cell lung cancer.  Immunol. Lett.  2018    PubMed ID: 29366663
4321  Shintani T, Higashisaka K, Maeda M, Hamada M, Tsuji R, Kurihara K, Kashiwagi Y, Sato A, Obana M, Yamamoto A, Kawasaki K, Lin Y, Kijima T, Kinehara Y, Miwa Y, Maeda S, Morii E, Kumanogoh A, Tsutsumi Y, Nagatomo I, Fujio Y.  Eukaryotic translation initiation factor 3 subunit C is associated with acquired resistance to erlotinib in non-small cell lung cancer.  Oncotarget  2018    PubMed ID: 30680067

トップへページトップへ
利用者成果(日)



戻る 戻る 理研トップページへ